10-Q: GB Sciences Reports Q2 2025 Results, Focuses on Drug Development and Intellectual Property

Sentiment:

Quarterly Report 27 November 2024 1:45 PM

GB Sciences reports its second quarter results for fiscal year 2025, highlighting ongoing drug development efforts and expansion of its intellectual property portfolio.

Capital raiseThe company's ability to continue as a going concern is dependent on obtaining additional financing.The company is pursuing several alternatives to address this situation, including the raising of additional funding through equity or debt financing.The company will likely require the sale of additional common stock or other securities to fund its operations.

Worse than expectedThe company reported a net loss for both the three and six-month periods, indicating worse than expected financial performance.The company's working capital deficit has increased, suggesting a worsening financial position.The company's ability to continue as a going concern is dependent on obtaining additional financing, highlighting a significant risk.

Summary

GB Sciences, a biopharmaceutical research and development company, released its financial results for the quarter ended September 30, 2024.
The company reported a net loss of $190,526 for the three-month period and a net loss of $475,544 for the six-month period.
General and administrative expenses decreased significantly to $157,790 for the quarter and $411,927 for the six months, reflecting cost-cutting measures.
The company's intellectual property portfolio includes eight U.S. and twelve foreign patents issued, two foreign patents allowed, and fifteen U.S. and forty-one foreign patent-pending applications.
GB Sciences is focused on developing plant-inspired medicines, with a primary focus on its Parkinson's disease therapy.
The company has a working capital deficit of $5,347,659 as of September 30, 2024, and has used $129,671 in operating activities for the six months ended September 30, 2024.
The company's ability to continue as a going concern is dependent on obtaining additional financing.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including net losses, a working capital deficit, and dependence on future financing. While there are positive aspects like intellectual property growth and preclinical study results, the overall sentiment is negative due to the company's financial instability and going concern risk.

Positives

General and administrative expenses decreased significantly, indicating cost control.
The company's intellectual property portfolio continues to expand with new patents issued and pending.
Preclinical studies for various therapeutic programs have shown positive results.
A licensing agreement with EndoPure Life Sciences provides a potential revenue stream.
The company is actively seeking development partners for its Parkinson's disease therapy.

Negatives

The company reported a net loss for both the three and six-month periods.
GB Sciences has a significant working capital deficit.
The company's ability to continue as a going concern is dependent on obtaining additional financing.
The company has a history of net losses and an accumulated deficit of $110,542,536.
There is substantial doubt about the company's ability to continue as a going concern.

Risks

The company's ability to continue as a going concern is dependent on securing additional financing.
There is no assurance that the company will be able to raise the necessary capital.
The company has a history of net losses and a significant accumulated deficit.
The company's working capital deficit poses a challenge to its operations.
The company is subject to risks associated with drug development, including clinical trial delays and regulatory hurdles.
The company is involved in a legal proceeding, the outcome of which is uncertain.

Future Outlook

The company anticipates that cash flows from operations will be insufficient to fund business operations for the next twelve-month period and will need to raise additional capital through equity or debt financing.

Management Comments

Management believes that its current and future plans provide an opportunity to continue as a going concern.
Management is continuing to seek sources of financing.

Industry Context

GB Sciences is operating in the biopharmaceutical industry, focusing on plant-inspired medicines, which is a growing area of interest. The company's focus on specific diseases like Parkinson's and MCAS aligns with the trend of targeted therapies. The licensing agreement with EndoPure is a common strategy for biotech companies to monetize their intellectual property.

Comparison to Industry Standards

The company's financial performance, with significant net losses and a working capital deficit, is not uncommon for early-stage biotech companies focused on research and development.
The company's reliance on external funding is typical for companies in this sector, especially those without commercialized products.
The expansion of the intellectual property portfolio is a positive sign, as patents are crucial for biotech companies.
The licensing agreement with EndoPure is a common strategy for biotech companies to monetize their intellectual property, similar to deals seen with companies like BioMarin and Vertex Pharmaceuticals.
The company's focus on specific diseases like Parkinson's and MCAS aligns with the trend of targeted therapies, similar to companies like Biogen and Alexion Pharmaceuticals.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Material Weakness	The company's disclosure controls and procedures were not effective due to material weaknesses: (1) as no member of our board of directors qualifies as an audit committee financial expert as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act; and (2) due to the fact the duties of the principal executive officer and the principal financial officer are consolidated in one person and therefore the Company lacks duel control within the duties of these two positions.	2024-09-30	This indicates a significant deficiency in the company's internal controls and could lead to inaccurate financial reporting.

Legal Proceedings

The company is involved in a lawsuit filed in the Eighth Judicial District Court in Clark County, Nevada, related to an alleged incident at the Teco Facility in May of 2020.

Related Party Transactions

As of September 30, 2024, $108,816 has been recorded in accounts payable related party, due to an entity controlled by a family member of Mr. John Poss, Chief Executive Officer of the Company.
As of September 30, 2024, $7,634 was owed to Mr. Poss for expenses incurred in connection with the business operations of the Company.
As of September 30, 2024, $7,498 has been recorded in accounts payable related party, due to Dr. Andrea Small Howard, President and Director, related to amounts owed for expenses incurred in connection with the business operations of the Company.

Stakeholder Impact

Shareholders face the risk of further dilution if the company raises additional capital through equity financing.
Employees may be impacted by the company's financial instability and potential restructuring.
Customers and suppliers may be affected by the company's ability to continue operations.
Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

The company will continue to seek development partners for its Parkinson's disease therapy.
The company will continue to advance its other therapeutic programs towards clinical trials.
The company will seek additional financing through equity or debt financing.

Key Dates

Date	Description
2017-10-23	Date of the Amended Production License Agreement and issuance of a 0% Promissory Note.
2020-03-24	Date of the Membership Interest Purchase Agreement (Teco MIPA) with AJE Management, LLC.
2020-08-10	Date of the Membership Interest Purchase Agreement (Nopah MIPA) with 483 Management, LLC.
2021-12-14	Date the Company received approval from the Nevada Cannabis Compliance Board for the transfer of cannabis licenses.
2021-12-31	Date the sales of the Nevada Subsidiaries formally closed.
2022-01-20	Date the Company repaid $500,000 of principal balances owed to an investor.
2022-03-04	Date of the Second Promissory Note Modification Agreement.
2022-04-11	Date the Company was served notice of a lawsuit.
2022-12-01	Israeli (IL) Patent was allowed, protecting Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2022-12-15	Australian (AU) Patent was allowed, protecting Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2023-02-03	GB Sciences first foreign patent protecting its proprietary cannabinoid-based formulations for Parkinsons disease was issued in China.
2023-02-20	Japanese (JP) Patent was allowed, protecting Cannabinoid-Containing Complex Mixtures for the treatment of Mast Cell Activation Syndrome (MCAS).
2023-03-09	Notice of Allowance was received for the Companys U.S. Patent Application No. 16/878,295.
2023-03-27	The Company and AJE Management entered into agreement regarding the note receivable.
2023-04-25	Japanese patent was issued for the use of GBSGBs Cannabinoid-Containing Complex Mixtures in the treatment of Parkinsons disease.
2023-09-01	The Company extended the expiration date and temporarily repriced 92,657,209 unexpired investor warrants.
2023-11-13	The Company reduced the conversion rate of the December 2020 convertible notes from $.03 per share to $.01 cent per share through December 31, 2023.
2024-01-22	Start date of the offering of additional 6% convertible notes.
2024-02-07	End date of the offering of additional 6% convertible notes.
2024-05-16	Date warrants were exercised and the Company recognized $3,462 as a deemed dividend.
2024-07-01	The Company received an additional $50,000 related to the January 2024 6% convertible notes.
2024-07-02	The Company received an additional $50,000 related to the January 2024 6% convertible notes.
2024-09-26	Date the Company entered into a licensing agreement with EndoPure Life Sciences, LLC.
2024-09-30	End of the quarterly period.
2024-11-27	Date of the report.

Keywords

biopharmaceutical, drug development, intellectual property, patents, Parkinson's disease, cannabinoid, licensing agreement, financial results, preclinical studies, working capital

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.